Regenxbio Inc. RGNX
$6.88
▲ +6.05% 24H
About
Regenxbio Inc. is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies to treat genetic disorders through its proprietary NAV Technology Platform. This platform utilizes recombinant adeno-associated virus (AAV) vectors, including AAV7, AAV8, AAV9, and over 100 novel va…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees353
TickerRGNX
Statistics
Market Cap$355.4M
Revenue (TTM)$170.4M
Net Income-$193.9M
Net Margin-113.8%
EPS$-3.76
P/E-1.77
P/S3.70
P/B15.39
EV/EBITDA-1.72
ROE-196.4%
Dividend Yield—
Price$6.88
Data: Twelve Data · Revenue = mcap / P/S